골암 치료 시장 : 규모, 점유율, 성장 및 산업 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of bone cancer treatment Market

The global bone cancer treatment market was valued at USD 1.31 billion in 2025 and is expected to grow from USD 1.40 billion in 2026 to USD 2.38 billion by 2034, registering a CAGR of 6.82% during the forecast period. North America dominated the global market with a 45.8% market share in 2025, supported by advanced oncology infrastructure, higher healthcare spending, and rapid adoption of innovative cancer therapies.

Bone cancer treatment includes therapies for primary bone cancers such as osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma, along with treatments for metastatic bone disease and bone-related complications. Growing research into targeted therapies, immunotherapies, antibody-drug conjugates, and orphan drugs is transforming the treatment landscape. Pharmaceutical companies continue investing heavily in clinical trials to improve survival rates and address the unmet medical needs of patients suffering from rare and aggressive bone cancers.

Bone Cancer Treatment Market Trends

One of the most significant trends shaping the bone cancer treatment market is the growing adoption of multimodal treatment strategies. Hospitals and cancer centers are increasingly combining chemotherapy, surgery, radiation therapy, targeted therapies, and supportive care to improve treatment outcomes. This integrated approach helps reduce recurrence, preserve limb function, and improve overall survival in patients with aggressive bone cancers.

Research collaborations are also increasing. In September 2025, Break Through Cancer invested USD 15 million to establish the Defying Osteosarcoma TeamLab, highlighting the industry's growing focus on advanced osteosarcoma research and innovative combination therapies.

Market Drivers

The rising prevalence of bone cancer and bone metastases continues to drive market expansion. Increasing diagnoses of osteosarcoma, Ewing sarcoma, and metastatic bone cancers have created sustained demand for chemotherapy drugs, targeted therapies, pain management solutions, and supportive care products.

Continuous product development further strengthens market growth. In January 2025, OS Therapies reported positive Phase 2b results for OST-HER2 in recurrent osteosarcoma patients, demonstrating improved event-free survival and supporting future commercialization opportunities.

Market Restraints

Despite steady growth, several challenges limit market expansion. Bone cancers often recur or metastasize after treatment, reducing long-term survival rates. Current chemotherapy-based regimens frequently produce severe side effects while offering limited improvements in advanced-stage disease.

Clinical studies continue to demonstrate the limitations of existing treatment protocols. Findings published during 2025 showed that intensifying conventional chemotherapy failed to significantly improve disease-free survival among high-risk osteosarcoma patients, emphasizing the urgent need for more effective therapies.

Market Opportunities

Rare cancer and orphan drug development programs are creating significant opportunities across the global market. Regulatory incentives, accelerated approval pathways, market exclusivity, and financial support encourage pharmaceutical companies to develop innovative therapies for osteosarcoma, chondrosarcoma, chordoma, and Ewing sarcoma.

In July 2025, Lithea Pharma received Orphan Drug Designation from the U.S. FDA for LIT1001, a novel therapy designed to deliver chemotherapy directly to osteosarcoma tumors, highlighting the growing investment in precision oncology.

Market Challenges

Developing effective therapies for recurrent and metastatic bone cancers remains difficult. Standard chemotherapy remains the primary treatment despite toxicity concerns and limited survival improvements. Clinical development for targeted therapies and immunotherapies requires lengthy trials due to the rarity of bone cancers, creating high development costs and regulatory hurdles for manufacturers.

Market Segmentation

Based on drug class, cytotoxic chemotherapy agents dominated the market in 2025 due to their widespread use in standard treatment regimens for osteosarcoma and Ewing sarcoma. The IDH inhibitors segment is expected to register the fastest growth throughout the forecast period.

By cancer type, osteosarcoma accounted for the largest market share owing to its higher incidence and intensive treatment requirements. The other bone cancers category is projected to witness healthy growth through 2034.

Based on age group, adults represented the largest revenue share due to higher treatment spending and greater use of advanced therapies, while the pediatric segment continues expanding steadily.

By therapy, chemotherapy maintained market dominance because it remains the foundation of treatment before and after surgery. However, immunotherapy is anticipated to experience faster growth as clinical research advances.

Based on route of administration, parenteral therapies dominated owing to the widespread use of intravenous oncology drugs administered in hospitals.

Hospital pharmacies remained the leading distribution channel, supported by specialized oncology care, infusion services, and cold-chain drug management.

Regional Outlook

North America remained the largest regional market, reaching USD 0.60 billion in 2025, supported by strong cancer research programs, early clinical trial access, and rapid adoption of innovative therapies. The U.S. continues to lead regional demand due to advanced healthcare infrastructure and increasing investment in rare cancer treatment.

Europe is expected to reach USD 0.38 billion in 2026, driven by specialized sarcoma treatment centers and improved clinical guidelines.

Asia Pacific is projected to reach USD 0.28 billion in 2026, supported by expanding cancer care infrastructure, improved diagnosis, and increasing access to advanced oncology treatments across China, Japan, and India.

Latin America and the Middle East & Africa are expected to witness moderate growth as awareness, diagnosis rates, and access to specialized cancer treatment continue improving.

Competitive Landscape

The bone cancer treatment market remains moderately fragmented, with leading pharmaceutical companies strengthening their portfolios through research, regulatory approvals, acquisitions, and pipeline expansion. Major companies include Amgen Inc., Novartis AG, Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Baxter International Inc., Viatris Inc., and GSK plc.

Recent industry developments include Iterion Therapeutics initiating a Phase 2 clinical trial for tegavivint in February 2026, Telix Pharmaceuticals beginning Phase 1 evaluation of TLX090 in October 2025, and OS Therapies expanding its oncology portfolio through the acquisition of Advaxis immunotherapy assets in April 2025.

Conclusion

The global bone cancer treatment market is expected to experience steady growth through 2034 as pharmaceutical companies continue investing in targeted therapies, immunotherapies, antibody-drug conjugates, and orphan drug programs for rare bone cancers. Although recurrence rates, limited treatment options, and lengthy clinical development remain significant challenges, ongoing innovation, supportive regulatory initiatives, and expanding research collaborations are expected to improve patient outcomes and create long-term growth opportunities across the global bone cancer treatment market.

Segmentation By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Region

By Drug Class * Cytotoxic Chemotherapy Agents

• Tyrosine Kinase Inhibitors (TKIs)
• Immune Checkpoint Inhibitors
• RANKL Inhibitors
• IDH Inhibitors
• Bisphosphonates
• Others

By Cancer Type * Osteosarcoma

• Ewing Sarcoma
• Chondrosarcoma
• Chordoma
• Others

By Age Group * Pediatric

• Adults

By Therapy * Chemotherapy

• Targeted Therapy
• Immunotherapy
• Others

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital Pharmacies

• Specialty Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region * North America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends
• 3.5. Market Challenges

4. Key Insights

• 4.1. Prevalence of Bone Cancer, By Countries/Region, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. New Product Launches, By Key Players
• 4.6. Pipeline Analysis, By Key Players

5. Global Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Cytotoxic Chemotherapy Agents
  • 5.1.2. Tyrosine Kinase Inhibitors (TKIs)
  • 5.1.3. Immune Checkpoint Inhibitors
  • 5.1.4. RANKL Inhibitors
  • 5.1.5. IDH Inhibitors
  • 5.1.6. Bisphosphonates
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.2.1. Osteosarcoma
  • 5.2.2. Ewing Sarcoma
  • 5.2.3. Chondrosarcoma
  • 5.2.4. Chordoma
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Therapy
  • 5.4.1. Chemotherapy
  • 5.4.2. Targeted Therapy
  • 5.4.3. Immunotherapy
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.5.1. Oral
  • 5.5.2. Parenteral
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Specialty Pharmacies
  • 5.6.3. Drug Stores & Retail Pharmacies
  • 5.6.4. Online Pharmacies
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Cytotoxic Chemotherapy Agents
  • 6.1.2. Tyrosine Kinase Inhibitors (TKIs)
  • 6.1.3. Immune Checkpoint Inhibitors
  • 6.1.4. RANKL Inhibitors
  • 6.1.5. IDH Inhibitors
  • 6.1.6. Bisphosphonates
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 6.2.1. Osteosarcoma
  • 6.2.2. Ewing Sarcoma
  • 6.2.3. Chondrosarcoma
  • 6.2.4. Chordoma
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Therapy
  • 6.4.1. Chemotherapy
  • 6.4.2. Targeted Therapy
  • 6.4.3. Immunotherapy
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.5.1. Oral
  • 6.5.2. Parenteral
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Specialty Pharmacies
  • 6.6.3. Drug Stores & Retail Pharmacies
  • 6.6.4. Online Pharmacies
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Cytotoxic Chemotherapy Agents
  • 7.1.2. Tyrosine Kinase Inhibitors (TKIs)
  • 7.1.3. Immune Checkpoint Inhibitors
  • 7.1.4. RANKL Inhibitors
  • 7.1.5. IDH Inhibitors
  • 7.1.6. Bisphosphonates
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 7.2.1. Osteosarcoma
  • 7.2.2. Ewing Sarcoma
  • 7.2.3. Chondrosarcoma
  • 7.2.4. Chordoma
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Therapy
  • 7.4.1. Chemotherapy
  • 7.4.2. Targeted Therapy
  • 7.4.3. Immunotherapy
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.5.1. Oral
  • 7.5.2. Parenteral
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Specialty Pharmacies
  • 7.6.3. Drug Stores & Retail Pharmacies
  • 7.6.4. Online Pharmacies
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Cytotoxic Chemotherapy Agents
  • 8.1.2. Tyrosine Kinase Inhibitors (TKIs)
  • 8.1.3. Immune Checkpoint Inhibitors
  • 8.1.4. RANKL Inhibitors
  • 8.1.5. IDH Inhibitors
  • 8.1.6. Bisphosphonates
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 8.2.1. Osteosarcoma
  • 8.2.2. Ewing Sarcoma
  • 8.2.3. Chondrosarcoma
  • 8.2.4. Chordoma
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Therapy
  • 8.4.1. Chemotherapy
  • 8.4.2. Targeted Therapy
  • 8.4.3. Immunotherapy
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.5.1. Oral
  • 8.5.2. Parenteral
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Specialty Pharmacies
  • 8.6.3. Drug Stores & Retail Pharmacies
  • 8.6.4. Online Pharmacies
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Cytotoxic Chemotherapy Agents
  • 9.1.2. Tyrosine Kinase Inhibitors (TKIs)
  • 9.1.3. Immune Checkpoint Inhibitors
  • 9.1.4. RANKL Inhibitors
  • 9.1.5. IDH Inhibitors
  • 9.1.6. Bisphosphonates
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 9.2.1. Osteosarcoma
  • 9.2.2. Ewing Sarcoma
  • 9.2.3. Chondrosarcoma
  • 9.2.4. Chordoma
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Therapy
  • 9.4.1. Chemotherapy
  • 9.4.2. Targeted Therapy
  • 9.4.3. Immunotherapy
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.5.1. Oral
  • 9.5.2. Parenteral
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Specialty Pharmacies
  • 9.6.3. Drug Stores & Retail Pharmacies
  • 9.6.4. Online Pharmacies
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Cytotoxic Chemotherapy Agents
  • 10.1.2. Tyrosine Kinase Inhibitors (TKIs)
  • 10.1.3. Immune Checkpoint Inhibitors
  • 10.1.4. RANKL Inhibitors
  • 10.1.5. IDH Inhibitors
  • 10.1.6. Bisphosphonates
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 10.2.1. Osteosarcoma
  • 10.2.2. Ewing Sarcoma
  • 10.2.3. Chondrosarcoma
  • 10.2.4. Chordoma
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Therapy
  • 10.4.1. Chemotherapy
  • 10.4.2. Targeted Therapy
  • 10.4.3. Immunotherapy
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.5.1. Oral
  • 10.5.2. Parenteral
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Specialty Pharmacies
  • 10.6.3. Drug Stores & Retail Pharmacies
  • 10.6.4. Online Pharmacies
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Amgen Inc.
  • 11.2.2. Novartis AG
  • 11.2.3. Pfizer Inc.
  • 11.2.4. Fresenius Kabi AG
  • 11.2.5. Hikma Pharmaceuticals PLC
  • 11.2.6. Teva Pharmaceutical Industries Ltd.
  • 11.2.7. Accord Healthcare Ltd.
  • 11.2.8. Baxter International Inc.
  • 11.2.9. Viatris Inc.
  • 11.2.10. GSK plc.